Physician profile
Freba Farhat
NPI 1992116016
$9,289.17
in general payments reported to CMS, 2019-2025
11 companies · $349 in 2025
The $349 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.95 · 2020: $263 · 2021: $471 · 2022: $394 · 2023: $15.47 · 2024: $7,727 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,338 · Travel and Lodging: $1,075 · Food and Beverage: $679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,337.50 |
| Travel and Lodging | $1,075.37 |
| Food and Beverage | $678.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $7,954.35 | 2024-2025 | Bimzelx |
| Abbvie INC. | $331.31 | 2020-2022 | |
| Janssen Biotech, INC. | $319.81 | 2019-2021 | |
| Genzyme Corporation | $269.16 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $116.56 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $112.53 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $82.38 | 2021 | |
| Janssen Scientific Affairs, LLC | $38.80 | 2020 | |
| Integra Lifesciences Corporation | $31.94 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Helsinn Therapeutics (U.S.), INC. | $16.86 | 2021 | |
| Organogenesis INC. | $15.47 | 2023 | Puraply |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Freba Farhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.